Glycoengineering insect cells for commercial recombinant glycoprotein production
Description: PUBLIC HEALTH RELEVANCE: Most recombinant protein drugs, or biologics, are manufactured using mammalian cells that can add the sugars required for these proteins to have their clinical effect. However, mammalian cell systems have some limitations and new biologics manufacturing platforms are needed to overcome this problem and to address the need for increased manufacturing capacity. This project will extend an academic lab effort, which has demonstrated that genetically engineered insect cells are potentially excellent alternative biologics manufacturing platforms, to the marketplace. New engineering strategies will be used to create insect cell lines optimized for commercial applications under conditions that will facilitate their future validation as new biologics manufacturing tools.
Funding type: research
Funder scheme: R43
Start date: 2013-09-30
End date: 2016-07-31
Investigator: CHRISTOPH GEISLER
Institution: GLYCOBAC, LLC
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 14
Funder award ID: R43GM102982
OpenAlex ID: G194065166